Pharmaceutical manufacturing giant Pfizer has announced that its breast cancer candidate palbociclib has received a new and coveted breakthrough product designation from the US Food and Drug ...
Andrew Baum, a former Citi analyst, has left his role as Pfizer's executive vice president and chief strategy and innovation ...
Hosted on MSN
This 6.5%-yielding dividend payer is sitting on a breakthrough investors haven’t priced in
Pfizer (PFE) offers a rare combination of a 6.5% dividend yield with a promising pipeline of oncology treatments and a new Lyme disease vaccine, trading at 9.1x forward P/E despite being 55% below its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results